Antibacterial drug discovery: is it all downhill from here?

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

L. Boyanova Clinical Microbiology and Infection

The greatest steps towards the discovery of Vibrio cholerae

P. Melin Clinical Microbiology and Infection

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Refugee crisis and re-emergence of forgotten infections in Europe

R. Cantón Clinical Microbiology and Infection

Genital Chlamydia trachomatis infections

P. Nordmann, L. Poirel Clinical Microbiology and Infection

E. Cambau, M. Drancourt Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Surveillance of Legionnaires’ disease in Austria

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Impact of antibiotic restrictions: the pharmaceutical perspective

Vector control: a cornerstone in the malaria elimination campaign

Training for the infectious diseases speciality in Norway

B. Gordts Clinical Microbiology and Infection

Laboratory diagnosis and biosafety issues of biological warfare agents

CMI editorial report 2011 Clinical Microbiology and Infection

Clinical and microbiological characteristics of Nocardiosis including those caused by emerging Nocardia species in Taiwan, 1998–2008 C.-K. Tan, C.-C.

Elements of design: the knowledge on which we build

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

G. Pappas Clinical Microbiology and Infection

Metagenomics and probiotics

Laboratory diagnosis of Clostridium difficile disease

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

The practice of travel medicine in Europe

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Current experience in treating invasive zygomycosis with posaconazole

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

A.P. Underwood, J. Green Clinical Microbiology and Infection

Antimicrobial drug development – the past, the present, and the future

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Clinical Microbiology and Infection

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Decision-making in otitis media in children, Part I: epidemiologic data and definitions for a reliable cost-effectiveness analysis Bernard Grenier Clinical.

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Antibacterial drug discovery: is it all downhill from here? S.J. Projan, D.M. Shlaes Clinical Microbiology and Infection Volume 10, Pages 18-22 (January 2004) DOI: 10.1111/j.1465-0691.2004.1006.x Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Contraction of the pharmaceutical industry with time, indicated by the number of companies that now form Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb and Aventis. Clinical Microbiology and Infection 2004 10, 18-22DOI: (10.1111/j.1465-0691.2004.1006.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions